Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2NET 2Endocrine 2Gynecologic 1

Conditions

Ovarian Neoplasms 328Fallopian Tube Neoplasms 153Carcinoma, Ovarian Epithelial 115Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Neoplasms 28Breast Neoplasms 27Peritoneal Neoplasms 24Brenner Tumor 24Carcinoma, Non-Small-Cell Lung 21Stomach Neoplasms 18Recurrence 17Neoplasm Metastasis 14Uterine Neoplasms 13Testicular Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Melanoma 9Testicular Germ Cell Tumor 8Central Nervous System Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Esophageal Neoplasms 7Carcinoma 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neurotoxicity Syndromes 6Carcinosarcoma 6

Interventions

pembrolizumab 2Magnetic Resonance Spectroscopy 2Irinotecan 2Fluorodeoxyglucose F18 2FAPI-46 2tivozanib 1taxane 1liposomal doxorubicin 1fludarabine 1entrectinib 1atezolizumab 1alectinib 1aldesleukin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Gemcitabine 1Etoposide 1Drug Therapy 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Paclitaxel × Gynecologic × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡